Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells
Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. The company developed vidutolimod and was acquired by Regeneron Pharmaceuticals in 2022.